What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?

World Journal of Gastroenterology

Volumn 20, Issue 5, 2014, Pages 1248-1258

  Lawrance, Ian C ^a,b  

^a FREMANTLE HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Anti tumour necrosis factor agents; Antiintegrin; Immunosuppression; Inflammatory bowel disease; Long term outcomes

Indexed keywords

6 METHYLTHIOINOSINE; ALLOPURINOL; AZATHIOPRINE; BUTYRIC ACID; CHEMOKINE RECEPTOR CCR9; CYCLOSPORIN; ENEMA; EPIDERMAL GROWTH FACTOR; INTEGRIN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; NICOTINE; PLACEBO; PREDNISOLONE; STEROID; TACROLIMUS; THIOGUANINE DERIVATIVE; THIOPURINE METHYLTRANSFERASE; TUMOR NECROSIS FACTOR INHIBITOR; VEDOLIZUMAB;

ARTICLE; CROHN DISEASE; DRUG EFFICACY; DRUG RESPONSE; ENZYME ACTIVITY; HUMAN; INFLAMMATORY BOWEL DISEASE; LYMPHOCYTE MIGRATION; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); T LYMPHOCYTE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ANTI-INTEGRIN; ANTI-TUMOUR NECROSIS FACTOR AGENTS; IMMUNOSUPPRESSION; INFLAMMATORY BOWEL DISEASE; LONG-TERM OUTCOMES;

ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; DRUG SUBSTITUTION; GASTROINTESTINAL AGENTS; HUMANS; T-LYMPHOCYTES; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893028322     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i5.1248     Document Type: Article

References (125)

1. Arts J, D'Haens G, Zeegers M, Van Assche G, Hiele M, D' Hoore A, Penninckx F, Vermeire S, Rutgeerts P. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 2004; 10: 73-78 [PMID: 15168804 DOI: 10.1097/00054725-20040300 0-00002]
2. Duerr RH, Barmada MM, Zhang L, Achkar JP, Cho JH, Hanauer SB, Brant SR, Bayless TM, Baldassano RN, Weeks DE. Evidence for an inflammatory bowel disease locus on chromosome 3p26: linkage, transmission/disequilibrium and partitioning of linkage. Hum Mol Genet 2002; 11: 2599-2606 [PMID: 12354785 DOI: 10.1093/hmg/11.21.2599]
3. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65 [PMID: 17241859 DOI: 10.1053/j.gastro.2006.11.041]
4. Mantzaris GJ, Christidou A, Sfakianakis M, Roussos A, Koilakou S, Petraki K, Polyzou P. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn' s disease. Inflamm Bowel Dis 2009; 15: 375-382 [PMID: 19009634 DOI: 10.1002/ibd.20777]
5. Trinder MW, Lawrance IC. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting. J Gastroenterol Hepatol 2009; 24: 1252-1257 [PMID: 19220669 DOI: 10.1111/j.1440-1746.2009.05786.x]
6. Pearce CB, Lawrance IC. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease. J Gastroenterol Hepatol 2007; 22: 1671-1677 [PMID: 17845695 DOI: 10.1111/j.1440-1746.2006.04739.x]
7. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333; quiz 591 [PMID: 16472588 DOI: 10.1053/ j.gastro.2005.11.030]
8. Willert RP, Lawrance IC. Use of infliximab in the prevention and delay of colectomy in severe steroid dependant and refractory ulcerative colitis. World J Gastroenterol 2008; 14: 2544-2549 [PMID: 18442203 DOI: 10.3748/wjg.14.2544]
9. Lichtenstein GR, Thomsen OØ, Schreiber S, Lawrance IC, Hanauer SB, Bloomfield R, Sandborn WJ. Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol 2010; 8: 600-609 [PMID: 20117244 DOI: 10.1016/ j.cgh.2010.01.014]
10. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-250 [PMID: 17634459 DOI: 10.1056/NEJMoa062897]
11. Panaccione R, Colombel JF, Sandborn WJ, Rutgeerts P, D' Haens GR, Robinson AM, Chao J, Mulani PM, Pollack PF. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther 2010; 31: 1296-1309 [PMID: 20298496 DOI: 10.1111/j.1365-2036.2010.04304.x]
12. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549 [PMID: 12047962 DOI: 10.1016/S0140-6736(02)08512-4]
13. Lawrance I. Certolizumab pegol in the treatment of CD, evidence from the PRECiSE clinical Trials. J Clin Inves 2011; 1: 459-465 [DOI: 10.4155/cli.10.33]
14. Walsh AJ, Weltman M, Burger D, Vivekanandarajah S, Connor S, Howlett M, Radford-Smith G, Selby W, Veillard AS, Grimm MC, Travis SP, Lawrance IC. Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2013; 7: e449-e456 [PMID: 23601754 DOI: 10.1016/j.crohns.2013.02.019]
15. Lawrance IC, Radford-Smith GL, Bampton PA, Andrews JM, Tan PK, Croft A, Gearry RB, Florin TH. Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience. J Gastroenterol Hepatol 2010; 25: 1732-1738 [PMID: 21039834 DOI: 10.1111/ j.1440-1746.2010.06407.x]
16. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104 [PMID: 11596589 DOI: 10.1056/NEJMoa011110]
17. Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007; 52: 1481-1484 [PMID: 17429728 DOI: 10.1007/s10620-006-9250-x]
18. Shale MJ, Seow CH, Coffin CS, Kaplan GG, Panaccione R, Ghosh S. Review article: chronic viral infection in the antitumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31: 20-34 [PMID: 19681818]
19. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, Henckaerts L, Van Assche G, Vermeire S, Rutgeerts P. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501-508 [PMID: 18832524]
20. Alfakih K, Brown B, Lawrance RA, Warburton P, Maqbool A, Walters K, Samani NJ, Ball SG, Balmforth AJ, Hall AS. Effect of a common X-linked angiotensin II type 2-receptor gene polymorphism (-1332 G/A) on the occurrence of premature myocardial infarction and stenotic atherosclerosis requiring revascularization. Atherosclerosis 2007; 195: e32-e38 [PMID: 17336987 DOI: 10.1016/j.atherosclerosis.2007.01.028]
21. Salama M, Lawrance IC. Stevens-Johnson syndrome complicating adalimumab therapy in Crohn's disease. World J Gastroenterol 2009; 15: 4449-4452 [PMID: 19764100 DOI: 10.3748/wjg.15.4449]
22. Mill J, Lawrance IC. Prevention of cancer in IBD - a balancing act. Minerva Gastroenterol Dietol 2013; 59: 261-272 [PMID: 23867946]
23. Trotter JL, Rodey GE, Gebel HM. Azathioprine decreases suppressor T cells in patients with multiple sclerosis. N Engl J Med 1982; 306: 365-366 [PMID: 6459531 DOI: 10.1056/ NEJM198202113060615]
24. Oger JJ, Antel JP, Kuo HH, Arnason BG. Influence of azathioprine (imuran) on in vitro immune function in multiple sclerosis. Ann Neurol 1982; 11: 177-181 [PMID: 6462102 DOI: 10.1002/ana.410110211]
25. Bacon PA, Salmon M. Modes of action of second-line agents. Scand J Rheumatol Suppl 1987; 64: 17-24 [PMID: 3124265 DOI: 10.3109/03009748709096717]
26. Mardini HE, Arnold GL. Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting. J Clin Gastroenterol 2003; 36: 390-395 [PMID: 12702978 DOI: 10.1097/0000 4836-200305000-00005]
27. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006; 130: 1047-1053 [PMID: 16618398 DOI: 10.1053/ j.gastro.2006.01.046]
28. Wright S, Sanders DS, Lobo AJ, Lennard L. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004; 53: 1123-1128 [PMID: 15247179 DOI: 10.1136/gut.2003.032896]
29. Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol 2004; 99: 1744-1748 [PMID: 15330913 DOI: 10.1111/ j.1572-0241.2004.30415.x]
30. Ragab AH, Gilkerson E, Myers M. The effect of 6-mercaptopurine and allopurinol on granulopoiesis. Cancer Res 1974; 34: 2246-2249 [PMID: 4843532]
31. Chevaux JB, Peyrin-Biroulet L, Sparrow MP. Optimizing thiopurine therapy in inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 1428-1435 [PMID: 20949566]
32. Seinen ML, de Boer NK, Smid K, van Asseldonk DP, Bouma G, van Bodegraven AA, Peters GJ. Allopurinol enhances the activity of hypoxanthine-guanine phosphoribosyltransferase in inflammatory bowel disease patients during lowdose thiopurine therapy: preliminary data of an ongoing series. Nucleosides Nucleotides Nucleic Acids 2011; 30: 1085-1090 [PMID: 22132961 DOI: 10.1080/15257770.2011.597371]
33. Sparrow MP, Hande SA, Friedman S, Lim WC, Reddy SI, Cao D, Hanauer SB. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005; 22: 441-446 [PMID: 16128682 DOI: 10.1111/j.1365-2036.2005.02583.x]
34. Allez M, Vermeire S, Mozziconacci N, Michetti P, Laharie D, Louis E, Bigard MA, Hébuterne X, Treton X, Kohn A, Marteau P, Cortot A, Nichita C, van Assche G, Rutgeerts P, Lémann M, Colombel JF. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010; 31: 92-101 [PMID: 19709098 DOI: 10.1111/ j.1365-2036.2009.04130.x]
35. D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106: 199-212; quiz 213 [PMID: 21045814]
36. Actis GC, Pellicano R, David E, Sapino A. Azathioprine, mucosal healing in ulcerative colitis, and the chemoprevention of colitic cancer: a clinical-practice-based forecast. Inflamm Allergy Drug Targets 2010; 9: 6-9 [PMID: 19906011 DOI: 10.2174/187152810791292863]
37. Hafraoui S, Dewit O, Marteau P, Cosnes J, Colombel JF, Modigliani R, Cortot A, Lémann M. Mycophenolate mofetil in refractory Crohn's disease after failure of treatments by azathioprine or methotrexate. Gastroenterol Clin Biol 2002; 26: 17-22 [PMID: 11938035]
38. Armuzzi A, Ahmad T, Ling KL, de Silva A, Cullen S, van Heel D, Orchard TR, Welsh KI, Marshall SE, Jewell DP. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut 2003; 52: 1133-1139 [PMID: 12865271 DOI: 10.1136/gut.52.8.1133]
39. Tan T, Lawrance IC. Use of mycophenolate mofetil in inflammatory bowel disease. World J Gastroenterol 2009; 15: 1594-1599 [PMID: 19340901 DOI: 10.3748/wjg.15.1594]
40. Neurath MF, Wanitschke R, Peters M, Krummenauer F, Meyer zum Büschenfelde KH, Schlaak JF. Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn's disease. Gut 1999; 44: 625-628 [PMID: 10205197 DOI: 10.1136/gut.44.5.625]
41. Fellermann K, Steffen M, Stein J, Raedler A, Hämling J, Ludwig D, Loeschke K, Stange EF. Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease. Aliment Pharmacol Ther 2000; 14: 171-176 [PMID: 10651657 DOI: 10.1046/j.1365-2036.2000.00695.x]
42. Fickert P, Hinterleitner TA, Wenzl HH, Aichbichler BW, Petritsch W. Mycophenolate mofetil in patients with Crohn' s disease. Am J Gastroenterol 1998; 93: 2529-2532 [PMID: 9860419 DOI: 10.1111/j.1572-0241.1998.00606.x]
43. Miehsler W, Reinisch W, Moser G, Gangl A, Vogelsang H. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease? Am J Gastroenterol 2001; 96: 782-787 [PMID: 11280551 DOI: 10.1111/j.1572-0241.2001.03622.x]
44. Hassard PV, Vasiliauskas EA, Kam LY, Targan SR, Abreu MT. Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Inflamm Bowel Dis 2000; 6: 16-20 [PMID: 10701145 DOI: 10.1097/00054725-200002000-00003]
45. Palaniappan S, Ford AC, Greer D, Everett SM, Chalmers DM, Axon AT, Hamlin PJ. Mycophenolate mofetil therapy for refractory inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 1488-1492 [PMID: 17924566 DOI: 10.1002/ ibd.20258]
46. Papay P, Reinisch W, Ho E, Gratzer C, Lissner D, Herkner H, Riss S, Dejaco C, Miehsler W, Vogelsang H, Novacek G. The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery. Am J Gastroenterol 2010; 105: 1158-1164 [PMID: 20010925 DOI: 10.1038/ajg.2009.673]
47. Baudouin-Legros M, Brouillard F, Cougnon M, Tondelier D, Leclerc T, Edelman A. Modulation of CFTR gene expression in HT-29 cells by extracellular hyperosmolarity. Am J Physiol Cell Physiol 2000; 278: C49-C56 [PMID: 10644511]
48. Wenzl HH, Hinterleitner TA, Aichbichler BW, Fickert P, Petritsch W. Mycophenolate mofetil for Crohn's disease: short-term efficacy and long-term outcome. Aliment Pharmacol Ther 2004; 19: 427-434 [PMID: 14871282 DOI: 10.1111/ j.1365-2036.2004.01856.x]
49. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995; 332: 292-297 [PMID: 7816064 DOI: 10.1056/ NEJM199502023320503]
50. Arora S, Katkov W, Cooley J, Kemp JA, Johnston DE, Schapiro RH, Podolsky D. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999; 46: 1724-1729 [PMID: 10430331]
51. Oren R, Moshkowitz M, Odes S, Becker S, Keter D, Pomeranz I, Shirin C, Reisfeld I, Broide E, Lavy A, Fich A, Eliakim R, Patz J, Villa Y, Arber N, Gilat T. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997; 92: 2203-2209 [PMID: 9399753]
52. Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis 2003; 35: 619-627 [PMID: 14563183 DOI: 10.1016/S1590-8658(03)00372-4]
53. Maté-Jiménez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroiddependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12: 1227-1233 [PMID: 11111780 DOI: 10.1097/0 0042737-200012110-00010]
54. Absah I, Faubion WA. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series. Inflamm Bowel Dis 2012; 18: 1488-1492 [PMID: 21882301 DOI: 10.1002/ibd.21885]
55. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-1610 [PMID: 15168370 DOI: 10.1053/ j.gastro.2004.02.070]
56. Mañosa M, Naves JE, Leal C, Cabré E, Moreno V, Lorenzo-Zuñiga V, Boix J, Domènech E. Does methotrexate induce mucosal healing in Crohn's disease? Inflamm Bowel Dis 2010; 16: 377-378 [PMID: 19575354 DOI: 10.1002/ibd.21015]
57. Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2005; (1): CD003459 [PMID: 15674908]
58. Balis FM, Mirro J, Reaman GH, Evans WE, McCully C, Doherty KM, Murphy RF, Jeffries S, Poplack DG. Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 1988; 6: 1882-1886 [PMID: 3199171]
59. Egan LJ, Sandborn WJ, Tremaine WJ, Leighton JA, Mays DC, Pike MG, Zinsmeister AR, Lipsky JJ. A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1597-1604 [PMID: 10594394 DOI: 10.1046/j.1365-2036.1999.00667.x]
60. Patel V, Macdonald JK, McDonald JW, Chande N. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009; (4): CD006884 [PMID: 19821390]
61. Chande N, MacDonald JK, McDonald JW. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2007; (4): CD006618 [PMID: 17943916]
62. Nathan DM, Iser JH, Gibson PR. A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration. J Gastroenterol Hepatol 2008; 23: 954-958 [PMID: 17559377 DOI: 10.1111/j.1440-1746.2007.05006.x]
63. El-Matary W, Vandermeer B, Griffiths AM. Methotrexate for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2009; (3): CD007560 [PMID: 19588435]
64. Klee CB, Draetta GF, Hubbard MJ. Calcineurin. Adv Enzymol Relat Areas Mol Biol 1988; 61: 149-200 [PMID: 2833077]
65. Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990; 144: 251-258 [PMID: 1688572]
66. Fellermann K, Tanko Z, Herrlinger KR, Witthoeft T, Homann N, Bruening A, Ludwig D, Stange EF. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 2002; 8: 317-324 [PMID: 12479646 DOI: 10.1097/00054725-200209000-00002]
67. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Am J Gastroenterol 2006; 101: 1048-1056 [PMID: 16573777 DOI: 10.1111/ j.1572-0241.2006.00524.x]
68. Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003; 17: 1273-1281 [PMID: 12755840 DOI: 10.1046/ j.1365-2036.2003.01534.x]
69. Ng SC, Arebi N, Kamm MA. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis 2007; 13: 129-134 [PMID: 17206694 DOI: 10.1002/ibd.20052]
70. Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis 2008; 14: 7-12 [PMID: 17879277 DOI: 10.1002/ibd.20263]
71. Bousvaros A, Kirschner BS, Werlin SL, Parker-Hartigan L, Daum F, Freeman KB, Balint JP, Day AS, Griffiths AM, Zurakowski D, Ferry GD, Leichtner AM. Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000; 137: 794-799 [PMID: 11113835 DOI: 10.1067/mpd.2000.109193]
72. Tamaki H, Nakase H, Matsuura M, Inoue S, Mikami S, Ueno S, Uza N, Kitamura H, Kasahara K, Chiba T. The effect of tacrolimus (FK-506) on Japanese patients with refractory Crohn's disease. J Gastroenterol 2008; 43: 774-779 [PMID: 18958546 DOI: 10.1007/s00535-008-2229-y]
73. Sandborn WJ, Present DH, Isaacs KL, Wolf DC, Greenberg E, Hanauer SB, Feagan BG, Mayer L, Johnson T, Galanko J, Martin C, Sandler RS. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebocontrolled trial. Gastroenterology 2003; 125: 380-388 [PMID: 12891539 DOI: 10.1016/S0016-5085(03)00877-1]
74. Fellermann K, Ludwig D, Stahl M, David-Walek T, Stange EF. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). Am J Gastroenterol 1998; 93: 1860-1866 [PMID: 9772045 DOI: 10.1111/j.1572-0241.1998.539_g.x]
75. Högenauer C, Wenzl HH, Hinterleitner TA, Petritsch W. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 2003; 18: 415-423 [PMID: 12940927 DOI: 10.1046/ j.1365-2036.2003.01662.x]
76. Ierardi E, Principi M, Francavilla R, Pisani A, Rendina M, Ingrosso M, Guglielmi FW, Panella C, Francavilla A. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol Ther 2001; 15: 371-377 [PMID: 11207512 DOI: 10.1046/ j.1365-2036.2001.00938.x]
77. Ziring DA, Wu SS, Mow WS, Martín MG, Mehra M, Ament ME. Oral tacrolimus for steroid-dependent and steroidresistant ulcerative colitis in children. J Pediatr Gastroenterol Nutr 2007; 45: 306-311 [PMID: 17873742 DOI: 10.1097/ MPG.0b013e31805b82e4]
78. Yamamoto S, Nakase H, Mikami S, Inoue S, Yoshino T, Takeda Y, Kasahara K, Ueno S, Uza N, Kitamura H, Tamaki H, Matsuura M, Inui K, Chiba T. Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 2008; 28: 589-597 [PMID: 18549460 DOI: 10.1111/j.1365-2036.2008.03764.x]
79. McSharry K, Dalzell AM, Leiper K, El-Matary W. Systematic review: the role of tacrolimus in the management of Crohn's disease. Aliment Pharmacol Ther 2011; 34: 1282-1294 [PMID: 21999607 DOI: 10.1111/j.1365-2036.2011.04873.x]
80. Gisbert JP, González-Lama Y, Maté J. Systematic review: Infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther 2007; 25: 19-37 [PMID: 17229218 DOI: 10.1111/ j.1365-2036.2006.03131.x]
81. Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006; 55: 1255-1262 [PMID: 16484504 DOI: 10.1136/ gut.2005.081794]
82. Hart AL, Plamondon S, Kamm MA. Topical tacrolimus in the treatment of perianal Crohn's disease: exploratory randomized controlled trial. Inflamm Bowel Dis 2007; 13: 245-253 [PMID: 17206671 DOI: 10.1002/ibd.20073]
83. Aberra FN, Stettler N, Brensinger C, Lichtenstein GR, Lewis JD. Risk for active tuberculosis in inflammatory bowel disease patients. Clin Gastroenterol Hepatol 2007; 5: 1070-1075 [PMID: 17627901 DOI: 10.1016/j.cgh.2007.04.007]
84. Baumgart DC, Macdonald JK, Feagan B. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev 2008; (3): CD007216 [PMID: 18646177]
85. Thin LW, Murray K, Lawrance IC. Oral tacrolimus for the treatment of refractory inflammatory bowel disease in the biologic era. Inflamm Bowel Dis 2013; 19: 1490-1498 [PMID: 23615528 DOI: 10.1097/MIB.0b013e318281f362]
86. Gustavsson A, Järnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlén P, Grännö C, Vilien M, Ström M, Verbaan H, Hellström PM, Magnuson A, Halfvarson J, Tysk C. Clinical trial: colectomy after rescue therapy in ulcerative colitis - 3-year follow-up of the Swedish-Danish controlled infliximab study. Aliment Pharmacol Ther 2010; 32: 984-989 [PMID: 20937043 DOI: 10.1111/j.1365-2036.2010.04435.x]
87. Casson DH, Eltumi M, Tomlin S, Walker-Smith JA, Murch SH. Topical tacrolimus may be effective in the treatment of oral and perineal Crohn's disease. Gut 2000; 47: 436-440 [PMID: 10940284 DOI: 10.1136/gut.47.3.436]
88. Lawrance IC. Topical agents for idiopathic distal colitis and proctitis. J Gastroenterol Hepatol 2011; 26: 36-43 [PMID: 21175791 DOI: 10.1111/j.1440-1746.2010.06497.x]
89. Lawrance IC. Novel topical therapies for distal colitis. World J Gastrointest Pharmacol Ther 2010; 1: 87-93 [PMID: 21577301 DOI: 10.4292/wjgpt.v1.i5.87]
90. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, Caprilli R, Colombel JF, Gasche C, Geboes K, Jewell DP, Karban A, Loftus EV, Peña AS, Riddell RH, Sachar DB, Schreiber S, Steinhart AH, Targan SR, Vermeire S, Warren BF. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19 (Suppl A): 5A-36A [PMID: 16151544]
91. Reinisch W, Sandborn WJ, Hommes DW, D'Haens G, Hanauer S, Schreiber S, Panaccione R, Fedorak RN, Tighe MB, Huang B, Kampman W, Lazar A, Thakkar R. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-787 [PMID: 21209123 DOI: 10.1136/gut.2010.221127]
92. Lawrance IC, Copeland TS. Rectal tacrolimus in the treatment of resistant ulcerative proctitis. Aliment Pharmacol Ther 2008; 28: 1214-1220 [PMID: 18761706 DOI: 10.1111/ j.1365-2036.2008.03841.x]
93. van Dieren JM, van Bodegraven AA, Kuipers EJ, Bakker EN, Poen AC, van Dekken H, Nieuwenhuis EE, van der Woude CJ. Local application of tacrolimus in distal colitis: feasible and safe. Inflamm Bowel Dis 2009; 15: 193-198 [PMID: 18825773 DOI: 10.1002/ibd.20644]
94. Kono T, Nomura M, Kasai S, Kohgo Y. Effect of ecabet sodium enema on mildly to moderately active ulcerative proctosigmoiditis: an open-label study. Am J Gastroenterol 2001; 96: 793-797 [PMID: 11280553 DOI: 10.1111/ j.1572-0241.2001.03624.x]
95. Lawrance IC. Ecabet sodium: a potential new agent in the management of distal colitis. J Gastroenterol Hepatol 2010; 25: 1182-1184 [PMID: 20594242 DOI: 10.1111/j.1440-1746.2010.06339. x]
96. Forbes A, Britton TC, House IM, Gazzard BG. Safety and efficacy of acetarsol suppositories in unresponsive proctitis. Aliment Pharmacol Ther 1989; 3: 553-556 [PMID: 2518869 DOI: 10.1111/j.1365-2036.1989.tb00247.x]
97. Auwerda JJ, Zijlstra FJ, Tak CJ, van den Ingh HF, Wilson JH, Ouwendijk RJ. Ridogrel enemas in distal ulcerative colitis. Eur J Gastroenterol Hepatol 2001; 13: 397-400 [PMID: 11338069 DOI: 10.1097/00042737-200104000-00016]
98. Vernia P, Cittadini M, Caprilli R, Torsoli A. Topical treatment of refractory distal ulcerative colitis with 5-ASA and sodium butyrate. Dig Dis Sci 1995; 40: 305-307 [PMID: 7851194 DOI: 10.1007/BF02065414]
99. Steinhart AH, Brzezinski A, Baker JP. Treatment of refractory ulcerative proctosigmoiditis with butyrate enemas. Am J Gastroenterol 1994; 89: 179-183 [PMID: 8304299]
100. Scheppach W, Sommer H, Kirchner T, Paganelli GM, Bartram P, Christl S, Richter F, Dusel G, Kasper H. Effect of butyrate enemas on the colonic mucosa in distal ulcerative colitis. Gastroenterology 1992; 103: 51-56 [PMID: 1612357]
101. Sandborn WJ, Tremaine WJ, Schroeder KW, Batts KP, Lawson GM, Steiner BL, Harrison JM, Zinsmeister AR. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 1994; 106: 1429-1435 [PMID: 8194687]
102. Ingram JR, Thomas GA, Rhodes J, Green JT, Hawkes ND, Swift JL, Srivastava ED, Evans BK, Williams GT, Newcombe RG, Courtney E, Pillai S. A randomized trial of nicotine enemas for active ulcerative colitis. Clin Gastroenterol Hepatol 2005; 3: 1107-1114 [PMID: 16271342 DOI: 10.1016/ S1542-3565(05)00849-9]
103. Sinha A, Nightingale J, West KP, Berlanga-Acosta J, Playford RJ. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 2003; 349: 350-357 [PMID: 12878742 DOI: 10.1056/NEJMoa013136]
104. van Dieren JM, Lambers ME, Kuipers EJ, Samsom JN, van der Woude CJ, Nieuwenhuis EE. Local immune regulation of mucosal inflammation by tacrolimus. Dig Dis Sci 2010; 55: 2514-2519 [PMID: 19949865 DOI: 10.1007/s10620-009-1047-2]
105. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003; 3: 521-533 [PMID: 12876555 DOI: 10.1038/nri1132]
106. Lawrance IC. Modifying T-cell trafficking to the intestinal as a potential management for inflammatory bowel disease. Expert Opin Investig Drugs 2012; 21: 975-984 [PMID: 22612537 DOI: 10.1517/13543784.2012.690030]
107. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-687 [PMID: 12297042 DOI: 10.1016/S0092-8674(02)00971-6]
108. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63-66 [PMID: 1538783 DOI: 10.1038/356063a0]
109. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996; 272: 60-66 [PMID: 8600538 DOI: 10.1126/ science.272.5258.60]
110. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-314 [PMID: 7507411 DOI: 10.1016/0092-8674(94)90337-9]
111. Arihiro S, Ohtani H, Suzuki M, Murata M, Ejima C, Oki M, Kinouchi Y, Fukushima K, Sasaki I, Nakamura S, Matsumoto T, Torii A, Toda G, Nagura H. Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease. Pathol Int 2002; 52: 367-374 [PMID: 12100519 DOI: 10.1046/ j.1440-1827.2002.01365.x]
112. Briskin M, Winsor-Hines D, Shyjan A, Cochran N, Bloom S, Wilson J, McEvoy LM, Butcher EC, Kassam N, Mackay CR, Newman W, Ringler DJ. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997; 151: 97-110 [PMID: 9212736]
113. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med 2009; 361: 2066-2078 [PMID: 19923578 DOI: 10.1056/ NEJMra0804647]
114. Kunkel EJ, Campbell JJ, Haraldsen G, Pan J, Boisvert J, Roberts AI, Ebert EC, Vierra MA, Goodman SB, Genovese MC, Wardlaw AJ, Greenberg HB, Parker CM, Butcher EC, Andrew DP, Agace WW. Lymphocyte CC chemokine receptor 9 and epithelial thymus-expressed chemokine (TECK) expression distinguish the small intestinal immune compartment: Epithelial expression of tissue-specific chemokines as an organizing principle in regional immunity. J Exp Med 2000; 192: 761-768 [PMID: 10974041 DOI: 10.1084/ jem.192.5.761]
115. Zabel BA, Agace WW, Campbell JJ, Heath HM, Parent D, Roberts AI, Ebert EC, Kassam N, Qin S, Zovko M, LaRosa GJ, Yang LL, Soler D, Butcher EC, Ponath PD, Parker CM, Andrew DP. Human G protein-coupled receptor GPR-9-6/ CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokinemediated chemotaxis. J Exp Med 1999; 190: 1241-1256 [PMID: 10544196 DOI: 10.1084/jem.190.9.1241]
116. Papadakis KA, Prehn J, Nelson V, Cheng L, Binder SW, Ponath PD, Andrew DP, Targan SR. The role of thymusexpressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol 2000; 165: 5069-5076 [PMID: 11046037]
117. Papadakis KA, Prehn J, Moreno ST, Cheng L, Kouroumalis EA, Deem R, Breaverman T, Ponath PD, Andrew DP, Green PH, Hodge MR, Binder SW, Targan SR. CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology 2001; 121: 246-254 [PMID: 11487533 DOI: 10.1053/ gast.2001.27154]
118. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348: 15-23 [PMID: 12510038 DOI: 10.1056/NEJMoa020696]
119. Tubridy N, Behan PO, Capildeo R, Chaudhuri A, Forbes R, Hawkins CP, Hughes RA, Palace J, Sharrack B, Swingler R, Young C, Moseley IF, MacManus DG, Donoghue S, Miller DH. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group. Neurology 1999; 53: 466-472 [PMID: 10449105 DOI: 10.1212/ WNL.53.3.466]
120. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-1925 [PMID: 16267322 DOI: 10.1056/NEJMoa043335]
121. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnálek P, Zádorová Z, Palmer T, Donoghue S. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348: 24-32 [PMID: 12510039 DOI: 10.1056/ NEJMoa020732]
122. Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, Donoghue S, Greenlees C, Subhani J, Amlot PL, Pounder RE. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001; 121: 268-274 [PMID: 11487536 DOI: 10.1053/gast.2001.26260]
123. Soler D, Chapman T, Yang LL, Wyant T, Egan R, Fedyk ER. The binding specificity and selective antagonism of Vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009; 330: 864-875 [PMID: 19509315 DOI: 10.1124/ jpet.109.153973]
124. Eksteen B, Adams DH. GSK-1605786, a selective smallmolecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn's disease. IDrugs 2010; 13: 472-781 [PMID: 20582872]
125. Walters MJ, Wang Y, Lai N, Baumgart T, Zhao BN, Dairaghi DJ, Bekker P, Ertl LS, Penfold ME, Jaen JC, Keshav S, Wendt E, Pennell A, Ungashe S, Wei Z, Wright JJ, Schall TJ. Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2010; 335: 61-69 [PMID: 20660125 DOI: 10.1124/jpet.110.169714]